New drug cocktail shows promise for Tough-to-Treat leukemia
NCT ID NCT03204188
First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This phase II study tested a combination of three drugs—ibrutinib, fludarabine, and pembrolizumab—in 15 people with high-risk or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how many patients achieved a complete response, meaning no signs of cancer. Ibrutinib was taken daily, fludarabine was given for five days, and pembrolizumab was infused every three weeks for up to a year. The study has been completed, and results are being analyzed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib, fludarabine, and pembrolizumab
What this could lead to
If successful, this combination could offer a more effective treatment option for people with high-risk or hard-to-treat CLL/SLL, potentially leading to longer-lasting remission.
What could go wrong
This was a small, early-phase study with only 15 participants, so results may not apply to everyone. The combination also carries risks of side effects, and it is not a cure since some patients may need to continue ibrutinib long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.